210 related articles for article (PubMed ID: 18534016)
1. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.
Alten R; Gram H; Joosten LA; van den Berg WB; Sieper J; Wassenberg S; Burmester G; van Riel P; Diaz-Lorente M; Bruin GJ; Woodworth TG; Rordorf C; Batard Y; Wright AM; Jung T
Arthritis Res Ther; 2008; 10(3):R67. PubMed ID: 18534016
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.
Zhang Y; Ren G; Guo M; Ye X; Zhao J; Xu L; Qi J; Kan F; Liu M; Li D
Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
5. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
7. A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy.
Goh AX; Bertin-Maghit S; Ping Yeo S; Ho AW; Derks H; Mortellaro A; Wang CI
MAbs; 2014; 6(3):765-73. PubMed ID: 24671001
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial.
Šenolt L; Leszczynski P; Dokoupilová E; Göthberg M; Valencia X; Hansen BB; Cañete JD
Arthritis Rheumatol; 2015 Jun; 67(6):1438-48. PubMed ID: 25707477
[TBL] [Abstract][Full Text] [Related]
9. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
Smolen JS; Agarwal SK; Ilivanova E; Xu XL; Miao Y; Zhuang Y; Nnane I; Radziszewski W; Greenspan A; Beutler A; Baker D
Ann Rheum Dis; 2017 May; 76(5):831-839. PubMed ID: 28087506
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
12. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P; Thompson E; Woodworth T; Smolen JS
Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
[TBL] [Abstract][Full Text] [Related]
13. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis.
Qi J; Ye X; Ren G; Kan F; Zhang Y; Guo M; Zhang Z; Li D
Mol Immunol; 2014 Feb; 57(2):59-65. PubMed ID: 24091292
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate.
Moreland LW; Pratt PW; Mayes MD; Postlethwaite A; Weisman MH; Schnitzer T; Lightfoot R; Calabrese L; Zelinger DJ; Woody JN
Arthritis Rheum; 1995 Nov; 38(11):1581-8. PubMed ID: 7488278
[TBL] [Abstract][Full Text] [Related]
16. ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
Takeuchi T; Tanaka Y; Erdman J; Kaneko Y; Saito M; Higashitani C; Smulders R; Lademacher C
Arthritis Res Ther; 2020 Oct; 22(1):252. PubMed ID: 33087159
[TBL] [Abstract][Full Text] [Related]
17. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
18. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
Baslund B; Tvede N; Danneskiold-Samsoe B; Larsson P; Panayi G; Petersen J; Petersen LJ; Beurskens FJ; Schuurman J; van de Winkel JG; Parren PW; Gracie JA; Jongbloed S; Liew FY; McInnes IB
Arthritis Rheum; 2005 Sep; 52(9):2686-92. PubMed ID: 16142748
[TBL] [Abstract][Full Text] [Related]
19. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
[TBL] [Abstract][Full Text] [Related]
20. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
